SUNESIS PHARMACEUTICALS ANNOUNCES PRECLINICAL MILESTONE PAYMENT IN BACE COLLABORATION WITH MERCK

Sunesis Pharmaceuticals, Inc. today announced that it has earned a $4.25 million payment from Merck & Co., Inc. for meeting certain preclinical milestones in the companies' collaboration to develop oral small molecule inhibitors of beta-amyloid converting enzyme (BACE), which is believed to play a key role in Alzheimer's disease.
Yahoo News